Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3703-76-2

Post Buying Request

3703-76-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3703-76-2 Usage

Originator

Hustazol,Yoshitomi,Japan,1972

Uses

Cloperastine Hydrochloride (C587213) is an anti-tussive drug as an over-the-counter cold medicine.

Manufacturing Process

The manufacture of a related compound is first described. 28.1 parts of pchloro-benzhydryl bromide are heated to boiling, under reflux and with stirring, with 50 parts of ethylene chlorohydrin and 5.3 parts of calcined sodium carbonate. The reaction product is extracted with ether and the ethereal solution washed with water and dilute hydrochloric acid. The residuefrom the solution in ether boils at 134° to 137°C under 0.2 mm pressure and is p-chloro-benzhydryl-(β-chloroethyl)ether.28.1 parts of this ether are heated with 12 parts of methylethylamine (100%) in a sealed tube for 4 hours at 110°C. The product of the reaction is extracted several times with dilute hydrochloric acid, the acid solution made alkaline, in the cold, with concentrated caustic soda solution and the base which separates taken up in ether. The ether extract is washed with concentrated potassium carbonate solution, evaporated down, and the residue distilled in vacuo. The product is β-methylethyl aminoethyl p-chlorobenzhydryl ether, BP 152° to 153°C/0.1 mm. Reaction with dimethylethylamine instead of methylethylamine leads directly to a quaternary compound, which type of compound can also be obtained by reacting the tertiary aminoethyl ether with reactive esters If 18 parts of piperidine are used instead of 12 parts of methylethylamine then the same procedure results in the formation of p-chloro-benzyhydril-(β- piperidino-ethyl)ether, boiling at 178° to 180°C under 0.15 mm pressure.

Therapeutic Function

Antitussive

Check Digit Verification of cas no

The CAS Registry Mumber 3703-76-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,0 and 3 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 3703-76:
(6*3)+(5*7)+(4*0)+(3*3)+(2*7)+(1*6)=82
82 % 10 = 2
So 3703-76-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2

3703-76-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine

1.2 Other means of identification

Product number -
Other names Cloperastine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3703-76-2 SDS

3703-76-2Synthetic route

piperidine
110-89-4

piperidine

(4-chlorophenyl)phenylmethyl 2-chloroethyl ether
5321-46-0, 132301-88-3

(4-chlorophenyl)phenylmethyl 2-chloroethyl ether

Cloperastine
3703-76-2

Cloperastine

Conditions
ConditionsYield
With sodium carbonate at 95℃; for 14h;80.7%
(4-chlorophenyl)phenylmethanol
119-56-2

(4-chlorophenyl)phenylmethanol

Cloperastine
3703-76-2

Cloperastine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sulfuric acid / toluene / 5 h / Reflux
2: sodium carbonate / 14 h / 95 °C
View Scheme
Cloperastine
3703-76-2

Cloperastine

2-<(2'-hydroxy-5'-biphenylyl)carbonyl>benzoic acid
84627-04-3

2-<(2'-hydroxy-5'-biphenylyl)carbonyl>benzoic acid

levocloperastine fendizoate

levocloperastine fendizoate

Conditions
ConditionsYield
In water; acetone for 2h; Solvent; Reflux;96.2%
triethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)silane
745783-97-5

triethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)silane

Cloperastine
3703-76-2

Cloperastine

1-(2-(phenyl(4-(triethylsilyl)phenyl)methoxy)ethyl)piperidine

1-(2-(phenyl(4-(triethylsilyl)phenyl)methoxy)ethyl)piperidine

Conditions
ConditionsYield
With 3,4,7,8-Tetramethyl-o-phenanthrolin; ferrous iodide; sodium t-butanolate In tetrahydrofuran at 120℃; for 12h; Schlenk technique; Glovebox; Inert atmosphere;88%
Cloperastine
3703-76-2

Cloperastine

2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methylbutanoic acid chloromethyl ester

2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methylbutanoic acid chloromethyl ester

1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methyl-1-oxobutoxy]methyl]piperidinium chloride

1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methyl-1-oxobutoxy]methyl]piperidinium chloride

Conditions
ConditionsYield
In dichloromethane at 70℃; for 1h;85%
Cloperastine
3703-76-2

Cloperastine

C20H13(2)H11ClNO*ClH

C20H13(2)H11ClNO*ClH

Conditions
ConditionsYield
Stage #1: Cloperastine With water-d2; lithium carbonate; triisopropylsilanethiol In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation;
Stage #2: With hydrogenchloride In 1-methyl-pyrrolidin-2-one
78%
Cloperastine
3703-76-2

Cloperastine

3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethylpropanoic acid iodomethyl ester

3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethylpropanoic acid iodomethyl ester

1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-1-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethyl-1-oxopropoxy]methyl]piperidinium iodide

1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-1-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethyl-1-oxopropoxy]methyl]piperidinium iodide

Conditions
ConditionsYield
In dichloromethane at 70℃; for 3h;78%
Cloperastine
3703-76-2

Cloperastine

sodium trimethylsilyldimethylsilanolate

sodium trimethylsilyldimethylsilanolate

1-(2-(phenyl(4-trimethylsilylphenyl)methoxy)ethyl)piperidine

1-(2-(phenyl(4-trimethylsilylphenyl)methoxy)ethyl)piperidine

Conditions
ConditionsYield
With bis(1,5-cyclooctadiene)nickel (0); Dimethyl(phenyl)phosphine In toluene at 70℃; for 18h; Schlenk technique; Sealed tube;59%
Cloperastine
3703-76-2

Cloperastine

levocloperastine

levocloperastine

Conditions
ConditionsYield
With di-p-anisoyl-L-tartaric acid In ethanol at 60℃; for 2h;
Cloperastine
3703-76-2

Cloperastine

C20H13(3)H11ClNO

C20H13(3)H11ClNO

Conditions
ConditionsYield
With tritium oxide In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation;
Cloperastine
3703-76-2

Cloperastine

(E)-1-ethyl-5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one

(E)-1-ethyl-5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one

A

2-((3S)-3-(1-(2-((4-chlorophenyl)(phenyl)methoxy)ethyl)-1,4,5,6-tetrahydropyridin-3-yl)-4,4,4-trifluorobutanoyl)-1-ethyl-5,5-dimethylpyrazolidin-3-one

2-((3S)-3-(1-(2-((4-chlorophenyl)(phenyl)methoxy)ethyl)-1,4,5,6-tetrahydropyridin-3-yl)-4,4,4-trifluorobutanoyl)-1-ethyl-5,5-dimethylpyrazolidin-3-one

B

2-(3-(1-(2-((4-chlorophenyl)(phenyl)methoxy)ethyl)-1,4,5,6-tetrahydropyridin-3-yl)-4,4,4-trifluorobutanoyl)-1-ethyl-5,5-dimethylpyrazolidin-3-one

2-(3-(1-(2-((4-chlorophenyl)(phenyl)methoxy)ethyl)-1,4,5,6-tetrahydropyridin-3-yl)-4,4,4-trifluorobutanoyl)-1-ethyl-5,5-dimethylpyrazolidin-3-one

Conditions
ConditionsYield
With tris(pentafluorophenyl)borate; scandium tris(trifluoromethanesulfonate); 2,6-bis[(4S,6S)-sec-butyl-2-oxazolin-2-yl]pyridine In dichloromethane at 80℃; for 24h; Inert atmosphere; stereoselective reaction;A n/a
B n/a

3703-76-2Relevant articles and documents

A left hand chlorine paipai Si Tingfenoak acid preparation method of the

-

Paragraph 0058; 0117-0122; 0161; 0172; 0187; 0202, (2017/08/25)

The invention discloses a preparation method of levo cloperastine fendizoate, which comprises the following steps: carrying out nucleophilic substitution reaction on 4-chlorobenzhydrol and 2-chloroethanol in a benzene organic solvent, so that an intermediate product is obtained; reacting the intermediate product with piperidine, so that racemic cloperastine is obtained; resolving the racemic cloperastine by using a resolving agent in a fatty alcohol solvent, so that levo cloperastine is obtained; and carrying out salt forming reaction on the levo cloperastine and a fendizoic acid, so that levo cloperastine fendizoate is obtained, wherein the resolving agent is an R-substituted dibenzoyl-L-tartaric acid, and R refers to alkyl, alkoxy, -Cl, -F, -Br or -H. In the method provided by the invention, in a fatty alcohol solvent, an R-substituted dibenzoyl-L-tartaric acid is adopted as a resolving agent for carrying out resolving on racemic cloperastine, and the resolving yield is high, so that the obtained levo cloperastine fendizoate has high optical purity, and has a high product yield.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3703-76-2